Regeneron Pharmaceuticals (REGN) will start testing combinations of its antibody drugs with the popular GLP-1 drugs introduced by Lilly (LLY) and rival Novo Nordisk (NVO) last year, writes Bloomberg’s Madison Muller..Health expers have begun raising concerns on the risk of “losing critical muscle mass” in certain patients using the weight loss drugs, added the story. “Regeneron will start testing two of its antibody drugs in combination with Wegovy to see if they preserve or help to build muscle,” noted the Bloomberg story.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk reports COMBINE 3 phase 3a trial achieved primary endpoint
- Tiziana Life files new patent application related to GLP-1ra, foralumab
- Novo Nordisk call volume above normal and directionally bullish
- Omega (NASDAQ:OMGA) Skyrockets After Research Deal With Novo Nordisk
- Novo Nordisk enters research pacts with Omega Therapeutics, Cellarity